Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ULTANE vs NITROUS OXIDE, USP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sevoflurane is a volatile general anesthetic that enhances inhibitory neurotransmission via GABA-A and glycine receptors, and inhibits excitatory neurotransmission via NMDA and nicotinic acetylcholine receptors, producing anesthesia, amnesia, and muscle relaxation.
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
Induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery
Anesthesia induction and maintenance,Procedural sedation and analgesia,Off-label: labor analgesia, treatment of severe pain in emergency settings
Inhalation: Induction, 0.5-3% sevoflurane in oxygen or oxygen/nitrous oxide; maintenance, 1.5-3% sevoflurane with or without nitrous oxide.
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
Terminal elimination half-life of inorganic fluoride is approximately 2-5 hours (mean 3.0 h) in adults; context: prolonged with obesity or renal impairment.
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Approximately 5% of sevoflurane is metabolized by cytochrome P450 (CYP2E1) to hexafluoroisopropanol (HFIP), carbon dioxide, and inorganic fluoride.
Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination.
Renal excretion of inorganic fluoride metabolites accounts for >95% of elimination; <5% excreted unchanged in urine.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Minimal binding to plasma proteins; <5% bound.
<0.5% (minimally bound; essentially unbound in plasma).
Volume of distribution at steady state: 0.5-1.5 L/kg (mean 1.0 L/kg); large Vd indicates extensive tissue distribution.
0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset).
Inhalation: ~100% bioavailable; no oral route.
Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane).
No dose adjustment required for GFR ≥30 m L/min; use with caution in GFR <30 m L/min due to potential for elevated fluoride concentrations, but no specific dose adjustment recommended.
No dose adjustment required; nitrous oxide is minimally excreted renally.
No dose adjustment required for Child-Pugh A or B; use with caution in Child-Pugh C, but no specific dose adjustment recommended.
No dose adjustment required; metabolism is minimal.
Induction: 2-4% sevoflurane in oxygen or oxygen/nitrous oxide, up to 8% for mask induction; maintenance: 1.5-3% with or without nitrous oxide.
Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%.
Elderly patients are more sensitive to sevoflurane; use lower doses for induction and maintenance, typical maintenance 0.5-2% sevoflurane.
Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia.
None
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
Risk of malignant hyperthermia; may cause respiratory depression; caution in patients with preexisting respiratory or cardiovascular disease; monitor for hepatotoxicity; use with caution in patients with renal impairment (elevated fluoride levels); sevoflurane may cause QT prolongation
Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard.
Known or suspected susceptibility to malignant hyperthermia,Known sensitivity to sevoflurane or other halogenated agents
Absolute: Known hypersensitivity, severe hematologic abnormalities (e.g., megaloblastic anemia), active vitamin B12 deficiency, need for prolonged oxygen therapy (e.g., pneumothorax, bowel obstruction), air trapping conditions (e.g., middle ear surgery, sinus infection). Relative: Pregnancy (first trimester), neurological disease, folate deficiency.
No specific food interactions with sevoflurane. However, patients should adhere to preoperative fasting guidelines (typically 6-8 hours for solids, 2 hours for clear liquids) to reduce aspiration risk during anesthesia.
No specific food interactions. However, patients with vitamin B12 deficiency or those on methotrexate should ensure adequate B12 and folate intake; nitrous oxide can deplete B12 stores. Heavy meals before sedation may increase risk of aspiration and nausea.
Sevoflurane (ULTANE) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic or fetotoxic effects at clinically relevant doses. In humans, limited data do not indicate an increased risk of major malformations with first-trimester exposure. However, use during the second and third trimesters may cause transient neonatal depression, including hypotonia and respiratory depression, due to placental transfer. Prolonged or repeated exposure should be avoided, especially during organogenesis, as with all volatile anesthetics.
Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery.
Sevoflurane is excreted into breast milk in low quantities. The milk-to-plasma (M/P) ratio has not been specifically determined for sevoflurane, but based on physicochemical properties, it is expected to be low. Due to rapid clearance and low oral bioavailability, the risk to a nursing infant is considered minimal after a single anesthetic dose. However, it is recommended to express and discard breast milk for 24 hours after anesthesia to minimize infant exposure.
Nitrous oxide is rapidly eliminated from plasma; low levels may pass into breast milk. No published M/P ratio. After a single dose, breastfeeding can be resumed once the mother is alert and has recovered from anesthesia. Limited data suggest no adverse effects on nursing infants. Caution with repeated or high doses.
During pregnancy, pharmacokinetic changes such as increased plasma volume, decreased protein binding, and increased cardiac output may necessitate dose adjustments. Sevoflurane requirements may be reduced by approximately 25-30% during pregnancy due to increased sensitivity to volatile anesthetics and decreased minimum alveolar concentration (MAC). Induction and maintenance doses should be titrated to effect, with close hemodynamic monitoring to avoid hypotension. No specific dose reduction is mandated, but careful titration is recommended.
No dose adjustments are typically required for short-term use. However, due to increased minute ventilation and decreased functional residual capacity in pregnancy, onset of action may be faster and depth of anesthesia may be greater. Consider using lower inspired concentrations (e.g., 30-50% N2O in O2) to avoid maternal hypoxia. Avoid prolonged exposure to reduce risk of fetal hypoxia and methemoglobinemia.
ULTANE (sevoflurane) is a volatile anesthetic with low blood-gas solubility, facilitating rapid induction and emergence. It is associated with a risk of malignant hyperthermia; have dantrolene available. Sevoflurane can degrade in carbon dioxide absorbents to compound A, which may cause renal injury; use fresh gas flows ≥2 L/min to minimize this risk. Monitor end-tidal sevoflurane concentration closely, as hypotension and respiratory depression are dose-dependent.
Nitrous oxide has a rapid onset (30-60 seconds) and offset; monitor for diffusion hypoxia upon discontinuation by administering 100% oxygen for 3-5 minutes. Avoid in patients with pneumothorax, bowel obstruction, middle ear surgery, or intracranial air due to risk of expansion. Use with caution in patients with vitamin B12 deficiency or methylenetetrahydrofolate reductase (MTHFR) mutations due to inactivation of methionine synthase. Nitrous oxide is a potent analgesic but weak anesthetic; always combine with an amnestic agent (e.g., benzodiazepine) for procedural sedation. In pediatric patients, use 30-50% concentration; higher concentrations may cause vomiting or excitement. Check waste gas scavenging systems to prevent occupational exposure.
You will receive this medication only under the supervision of an anesthesia professional,Do not eat or drink before surgery as instructed by your doctor,You may experience dizziness or drowsiness after waking; do not drive for 24 hours,Report any history of kidney disease or adverse reactions to anesthesia,Inform your doctor if you are pregnant or breastfeeding,You will be monitored throughout the procedure for vital signs and safety
You may feel lightheaded, euphoric, or have tingling sensations; this is normal and will resolve quickly after stopping the gas.,You will receive oxygen after the procedure to prevent a sudden drop in oxygen levels.,Do not eat a heavy meal for 2-3 hours before sedation to reduce the risk of nausea or vomiting.,Inform your healthcare provider if you have a history of vitamin B12 deficiency, anemia, or lung problems (e.g., pneumothorax).,You should not drive, operate machinery, or make important decisions for 24 hours after sedation.
No interactions on record
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"Nitrous oxide, an NMDA receptor antagonist and anesthetic gas, can enhance the central nervous system (CNS) depressant effects of difenoxin, an opioid antidiarrheal that acts on mu-opioid receptors. This combination increases the risk of profound sedation, respiratory depression, and coma, particularly in elderly or debilitated patients. Concurrent use may also exacerbate hypotension and bradycardia due to synergistic effects on the autonomic nervous system."
"Nitrous oxide (N2O) is an NMDA receptor antagonist and can inhibit the enzyme methionine synthase, leading to decreased methionine and increased homocysteine levels. Lamotrigine, a sodium channel blocker and glutamate release inhibitor, has proconvulsant effects at high doses and can lower the seizure threshold. The combination may increase the risk of seizures and neurotoxicity, particularly in patients with underlying epilepsy or rapid dose escalation of lamotrigine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ULTANE vs NITROUS OXIDE, USP, answered by our medical review team.
ULTANE is a Inhalational Anesthetic that works by Sevoflurane is a volatile general anesthetic that enhances inhibitory neurotransmission via GABA-A and glycine receptors, and inhibits excitatory neurotransmission via NMDA and nicotinic acetylcholine receptors, producing anesthesia, amnesia, and muscle relaxation.. NITROUS OXIDE, USP is a Inhalational Anesthetic that works by Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ULTANE and NITROUS OXIDE, USP depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ULTANE is: Inhalation: Induction, 0.5-3% sevoflurane in oxygen or oxygen/nitrous oxide; maintenance, 1.5-3% sevoflurane with or without nitrous oxide.. The standard adult dose of NITROUS OXIDE, USP is: Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ULTANE and NITROUS OXIDE, USP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ULTANE is classified as Category C. Sevoflurane (ULTANE) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic or fetotoxic effects at clinically relevant doses. In humans, limit. NITROUS OXIDE, USP is classified as Category C. Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data sh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.